Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to the Terms of Convertible Loan Stock

8 Dec 2017 07:00

RNS Number : 7627Y
Sopheon PLC
08 December 2017
 

Embargoed Release: 07:00hrs Friday 8 December

 

 

SOPHEON PLC

 

AMENDMENT TO THE TERMS OF CONVERTIBLE LOAN STOCK

 

Sopheon plc ("Sopheon", the "Company" or the "Group") announces that it has reached agreement with the holders of its remaining £1.94m of convertible unsecured loan stock (the "Loan Stock") to convert it into equity by the end of 2017. 

 

As previously announced, in 2009 and 2011, the Company issued a total of £2m of Loan Stock to a group of investors including members of the Board and senior management team. The Loan Stock, which carries an interest coupon at a rate of 8 percent per annum, is currently due to mature on 31 January 2019, and has a conversion price of 76.5p per ordinary share of 20p each in the Company ("Ordinary Shares"). Board members with an interest in the Loan Stock are Barry Mence (£640,000), Andrew Michuda (£45,000), Arif Karimjee (£27,000) and Stuart Silcock (£200,000). Rivomore Limited, a current substantial shareholder in the Company, has an interest in the Loan Stock of £640,000.

 

Proposals have yesterday been put to the holders of the Loan Stock that would reconstitute the instrument such that it would automatically convert to equity on 22 December 2017, at the conversion price stated above, resulting in the issue of 2,535,947 new Ordinary Shares. This change will improve the profile of the Group's year end balance sheet and simplify the capital structure, as well as eliminating the interest charge going forward. In conjunction with this proposed amendment, a one-off payment of 8 percent of the face value of the Loan Stock will be made to holders of the Loan Stock in cash amounting to approximately £155,000, in recognition of the loss of their interest and repayment rights as a result of the early conversion. Irrevocable undertakings have been received from holders representing almost £1.7m of the Loan Stock, being over 85 per cent of the Loan Stock in issue, to vote in favour of a resolution to authorise the amendment of the Loan Stock instrument as described above at a forthcoming meeting of the Loan Stock holders on 22 December 2017 (the "Meeting").

 

The modification of the terms of the Loan Stock constitutes a related party transaction for the purposes of AIM Rule 13. In accordance with the AIM Rules for Companies, Daniel Metzger, as the director independent with respect to this transaction, having consulted with the Company's Nominated Adviser, finnCap Limited, considers that the amendment to the terms of the Loan Stock are fair and reasonable insofar as the Company's shareholders are concerned.

 

Following formal approval by Loan Stock holders at the Meeting, application will be made for the 2,535,947 new Ordinary Shares to be admitted to trading on AIM, and dealings expected to commence on 27 December 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. A further announcement will be made following the Meeting.

 

 

Sopheon's Chairman, Barry Mence said: "I am delighted and grateful that our convertible loan stock holders have continued to show such solid support for the Company, as they have through the last several years of our development as a business. With these changes we will enter 2018 with a clearer capital structure and an enhanced balance sheet."

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener / Camille Gochez (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEADAXELDXFAF
Date   Source Headline
10th Jun 20217:00 amRNSAGM Statement
3rd Jun 20211:50 pmRNSIssue of Equity
2nd Jun 20217:00 amRNSSopheon Deployed Globally at The 3M Company
14th May 202110:11 amRNSGrant of Options / PDMR dealing
14th Apr 20217:00 amRNSLaunch of Accolade for Smart Products
9th Apr 20214:15 pmRNSIssue of Equity
31st Mar 20217:00 amRNSDirectorate Change
29th Mar 20212:30 pmRNSDirector Shareholdings
24th Mar 20217:00 amRNSFinal Results
3rd Mar 202111:02 amRNSHolding(s) in Company
2nd Mar 202112:12 pmRNSHolding(s) in Company
26th Feb 20214:20 pmRNSResult of Secondary Placing
26th Feb 20211:36 pmRNSProposed Secondary Placing
8th Feb 20214:30 pmRNSHolding(s) in Company
28th Jan 20217:00 amRNSSopheon extend innovation leadership with Simplot
25th Jan 20217:00 amRNSTrading Update
5th Nov 20207:00 amRNSRelease of Accolade version 13.2
12th Oct 20207:00 amRNSSeasoned Cloud & Industry Executive added to Team
9th Sep 20209:55 amRNSOrion Engineered Carbons works with Sopheon
1st Sep 202011:38 amRNSDirector Shareholdings
28th Aug 202012:39 pmRNSIssue of Equity
27th Aug 20207:00 amRNSInterim Results
30th Jul 20207:00 amRNSMondelez Partnership
13th Jul 202011:41 amRNSGrant of Options/PDMR Dealing
11th Jun 202011:28 amRNSResult of AGM
9th Jun 202012:00 pmRNSIssue of Equity & Director/PDMR Shareholding
28th May 20207:29 amRNSProgressive publishes new research
28th May 20207:00 amRNSNew Sopheon Release Integrating Microsoft Teams
15th May 202010:01 amRNSIssue of Equity
15th May 20207:00 amRNSAGM Notice and Update
3rd Apr 202011:17 amRNSDirector Shareholdings
25th Mar 20201:38 pmRNSIssue of Equity
19th Mar 20204:46 pmRNSIssue of Equity
19th Mar 20207:00 amRNSFinal Results
28th Jan 20209:05 amRNSSecond Price Monitoring Extn
28th Jan 20209:00 amRNSPrice Monitoring Extension
28th Jan 20207:00 amRNSTrading Update
10th Jan 20201:00 pmRNSIssue of Equity
11th Dec 20197:00 amRNSTrading Update
10th Oct 201912:00 pmRNSIssue of Equity
1st Oct 201912:00 pmRNSIssue of Equity
20th Sep 20194:45 pmRNSIssue of Equity
22nd Aug 20192:06 pmRNSSecond Price Monitoring Extn
22nd Aug 20192:01 pmRNSPrice Monitoring Extension
22nd Aug 201911:05 amRNSSecond Price Monitoring Extn
22nd Aug 201911:00 amRNSPrice Monitoring Extension
22nd Aug 20199:05 amRNSSecond Price Monitoring Extn
22nd Aug 20199:00 amRNSPrice Monitoring Extension
22nd Aug 20197:00 amRNSHalf-year Report
12th Aug 201910:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.